With regard to COVID-19, Xue et al. (Zhu et al., 2020b) showed that the duration of viral loss and hospital stay was significantly shorter in patients treated with arbidol, Lopinavir/Ritonavir, and recombinant interferon alpha-2B triple antiviral therapy compared to those treated without arbidol. This evidence concerns the gene IFNA2 and COVID-19.